Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | CA4 | P22748 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lithium Ion SCHEMBL2334009 | 1.00 | — | — | |
| Lithium Ion SCHEMBL31243768 | 0.96 | — | — | |
| SCHEMBL9181254 | 0.92 | CA1 (0.43) | CA1CA2CYP3A4TSHRNFKB1 | |
| SCHEMBL6512986 | 0.92 | CA1 (0.43) | CA1CA2CYP3A4TSHRNFKB1 | |
| SCHEMBL782854 | 0.92 | CA1 (0.43) | CA1CA2CYP3A4TSHRNFKB1 | |
| SCHEMBL25268289 | 0.92 | CA1 (0.43) | CA1CA2CYP3A4TSHRNFKB1 | |
| Silver SCHEMBL25782 | 0.92 | — | — | |
| SCHEMBL17536062 | 0.92 | CA1 (0.43) | CA1CA2CYP3A4TSHRNFKB1 | |
| SCHEMBL3532262 | 0.92 | CA1 (0.43) | CA1CA2CYP3A4TSHRNFKB1 | |
| SCHEMBL11543889 | 0.92 | CA1 (0.43) | CA1CA2CYP3A4TSHRNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116626008-A | Qualitative and quantitative detection method for lithium isobutyrate-L-proline salt based on fluorescence characteristic | 安域生物科技(杭州)有限公司 | 2023-08-22 | — | — | CN | disclosed |
| US-7777071-B2 | Production of carnitine conjugate intermediates | SSV THERAPEUTICS, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20090012160-A1 | Carnitine Conjugates As Dual Prodrugs, Methods Of Production And Uses Thereof | SSV THERAPEUTICS, INC. | 2009-01-08 | — | — | US | disclosed |
| WO-2008018877-A1 | CARNITINE CONJUGATES AS DUAL PRODRUGS, METHODS OF PRODUCTION AND USES THEREOF | SSV THERAPEUTICS, INC. (US) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012160-A1 | Carnitine Conjugates As Dual Prodrugs, Methods Of Production And Uses Thereof | CPT1B, CRAT, CPT2 | CA1 1656/4885CA2 1800/4885CYP3A4 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.